AstraZeneca - Biologics Day Interviews With Senior Management

LONDON, December 7 /PRNewswire-FirstCall/ -- David Brennan, AstraZeneca CEO, and senior management from AstraZeneca (LSE: AZN) (NYSE: AZN) and MedImmune discuss opportunities in the biologics field, R&D and portfolio progress plus the Group's current focus and priorities. Video interviews and transcripts are available now on http://www.cantos.com.

It's free to view. All you need to do is register at http://www.cantos.com.

Cantos.com is an online financial website featuring in-depth interviews, documentaries and webcasts with senior company executives addressing the critical issues facing their businesses. If you would like to contact us, please email [email protected] or phone +44-207-936-1333.

SOURCE AstraZeneca

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.